AKD

Approach to elucidate the effect of ketamine on treatment resistant depression - AKD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021190007

Enrollment

Registered

2019-07-26

Start date

2019-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory depression depression

Interventions

1.iv both ketamine 0.5 mg/kg and midazolam 0.04 mg/kg for 40 min 2. taking a blood sample

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with refractory depression diagnosed by psychiatrists

Exclusion criteria

Exclusion criteria: 1. patients who has allergy to ketamine 2, patients who are diagnosed with glaucoma or high pressure of increased intracranial pressure

Design outcomes

Primary

Measure	Time frame
effect of ketamine on refractory depression	—

Secondary

Measure	Time frame
assessment of biomarkers after intravenous injection of ketamine	—

Contacts

Public ContactTakashi Kudo

Hirosaki University Hospital

takf5@hirosaki-u.ac.jp+81-172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

AKD